Willibald Schröder

2PUBLICATIONS
28CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

|Nov 04, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.

Jacobus Pfisterer, Florence Joly, Gunnar Kristensen

|Aug 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant.

Pauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer

Pageof 1

Frequent Collaborators

2 joint publications

Jacobus Pfisterer

2 joint publications

Lars Hanker

2 joint publications

Felix Hilpert

2 joint publications

Tjoung-Won Park-Simon